Results 91 to 100 of about 5,495 (171)

Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
After discontinuation of semaglutide or tirzepatide, weight regain averaged 1.04 kg/month. Based on a linear model, half of treatment‐associated weight loss was projected to return by approximately 7.5 months and baseline weight by approximately 15 months, highlighting the need for early monitoring and maintenance planning.
Chia Siang Kow, Kaeshaelya Thiruchelvam, Dinesh Sangarran Ramachandram, Abdullah Faiz Zaihan   +3 more
wiley   +1 more source

Potential for imaging the high-affinity state of the 5-HT1B receptor: a comparison of three PET radioligands with differing intrinsic activity

EJNMMI Research, 2019
Background Over the last decade, a few radioligands have been developed for PET imaging of brain 5-HT1B receptors. The 5-HT1B receptor is a G-protein-coupled receptor (GPCR) that exists in two different agonist affinity states.
Anton Lindberg, Ryosuke Arakawa, Tsuyoshi Nogami, Sangram Nag, Magnus Schou, Charles S. Elmore, Lars Farde, Victor W. Pike, Christer Halldin   +8 more
doaj   +1 more source

Effectiveness and tolerability of fenfluramine in pediatric and adult patients with developmental and epileptic encephalopathies: A multicenter, retrospective, real‐world clinical‐practice study

Epilepsia, Volume 67, Issue 9, Page 4536-4550, September 2026.
Abstract Objective Developmental and epileptic encephalopathies (DEEs) are characterized by drug‐resistant seizures and developmental slowing/regression. We examined the efficacy and tolerability of fenfluramine (FFA) in pediatric and adult patients with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and other DEEs.
Vicente Villanueva, Elena González‐Alguacil, Patricia Smeyers, Sara Hernández, Victor Soto‐Insuga, Alejandro Fernández‐Cabrera, Laura Olivié, Teresa de Santos, Beatriz Parejo, Lucas Iacampo, Belén Ortuño, Javier Aparicio, Montserrat Fuentes, Juan Rodriguez‐Uranga, Paula Martínez‐Agredano, José Carlos Estévez, Angel Aledo‐Serrano, Rocio Martin‐Alvarez, David Conejo, Belen Baena, Blanca Mercedes‐Álvarez, Yolanda López, Alba Sierra‐Marcos, Rocio Trincado‐Lamuño, Mouna Ennazeh, Jesús González de la Aleja, Julia Renau, Maria Dolores Castro‐Vilanova, Fátima Romero‐Aguilera, José M. Serratosa   +29 more
wiley   +1 more source

Reintroducing Fenfluramine as a Treatment for Seizures: Current Knowledge, Recommendations and Gaps in Understanding

Neuropsychiatric Disease and Treatment, 2023
Gianluca Dini,1 Giuseppe Di Cara,1 Pietro Ferrara,2 Pasquale Striano,3 Alberto Verrotti1 1Department of Pediatrics, University of Perugia, Perugia, Italy; 2Department of Pediatrics, Campus Bio-Medico University, Rome, Italy; 3Pediatric Neurology and ...
Dini G, Di Cara G, Ferrara P, Striano P, Verrotti A   +4 more
doaj  

Pituitary-adrenal responses to combined oral D-fenfluramine and intravenous naloxone in humans

, 1998
1. Fenfluramine is an optically active 5-hydroxytryptamine (5-HT) releaser and re-uptake inhibitor. Increased brain 5-HT mediates appetite suppression, the D enantiomer being more active than L- Or DL-fenfluramine.
Hockings, GI, Walters, MM, Torpy, DJ, Jackson, RV, Crosbie, GV, Grice, JE   +5 more
core   +1 more source

The discriminative stimulus properties of fenfluramine: evidence for serotonergic involvement/ [PDF]

, 1981
The first drug to be found useful in suppressing appetite was amphetamine (Lesser and Meyerson, 1938). Amphetamine has potent central stimulant, cardiovascular, hyperthermic and anorectic properties, to all of which tolerance develops upon repeated use ...
Mcelroy, John F.
core   +1 more source

Spectroscopic and Thermoanalytical Characterization of (+)-Fenfluramine Hydrochloride

, 1996
The Characterization of (+)-Fenfluramine Hydrochloride was made by both spectroscopic and thermoanalytical ...
MARINI, AMEDEO, BERBENNI, VITTORIO, BRUNI, GIOVANNA, BINI, MARCELLA, M. Villa, A. Magnone Grato   +5 more
core  

Event-related potentials and monoamines in autistic children on a clinical trial of fenfluramine [PDF]

, 1990
Introduction: As autistic persons have problems with selecting and encoding meaningful stimuli and multi-centre studies (Ritvo et al., 1983, 1986) had reported mild behavioural improvements following treatment with fenfluramine, event-related potential ...
Clark, C.R., Walker, M.K., Oades, R.D., Kapoor, V., Stern, L.M.   +4 more
core  

Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study

, 1999
Background: Functional alterations in the central serotonergic system have been reported in schizophrenia bur no conclusive data have been provided.
MAJ M., Tortorella, Alfonso Antonio Vincenzo, CASSANDRO P, BORRIELLO R, MONTELEONE P   +4 more
core   +2 more sources

Complex epilepsy phenotype associated with chromosome 2q24.2‐q24.3 deletion involving sodium channel gene cluster

Annals of the Child Neurology Society
Objective The 2q24.2‐24.3 chromosome region encodes sodium channel genes important in severe childhood epilepsy, notably SCN1A linked to Dravet syndrome (DS). However, the roles of other genes, either within the SCN cluster or in the segments proximal to
Rima Madan, Fiorella S. Guido, Nicole Brescia   +2 more
doaj   +1 more source